Costs and Benefits of Including Inactivated in Addition to Oral Poliovirus Vaccine in Outbreak Response After Cessation of Oral Poliovirus Vaccine Use

MDM Policy and Practice

Volumn 2, Issue 1, 2017, Pages

  Duintjer Tebbens, Radboud J ^a   Thompson, Kimberly M ^a  

^a and Spiritual Formation   (United States)

Author keywords

dynamic modeling; eradication; health economics; IPV; OPV cessation; polio; risk management

Indexed keywords

EID: 85019239474     PISSN: None     EISSN: 23814683     Source Type: Journal    
DOI: 10.1177/2381468317697002     Document Type: Article

References (67)

1. Nathanson N, Kew OM., From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol. 2010;172(11):1213–29.
2. Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SG, Cochi SL, Thompson KM., Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal. 2013;23(4):703–49.
3. Vidor E, Plotkin SA., Poliovirus vaccine—inactivated. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 6th ed. Philadelphia: Saunders Elsevier; 2013. p 573–97.
4. Sutter RW, Kew OM, Cochi SL, Aylward RB., Poliovirus vaccine – Live. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. Sixth ed. Philadelphia: Saunders Elsevier 2013:598–645.
5. Thompson KM, Duintjer Tebbens RJ. National choices related to inactivated poliovirus vaccine, innovation, and the end game of global polio eradication. Exp Rev Vaccines. 2014;13(2):221–34.
6. Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SG, Kim JH, Cochi SL., Pre-eradication vaccine policy options for poliovirus infection and disease control. Risk Anal. 2013;33(4):516–43.
7. Patriarca PA, Wright PF, John TJ., Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis. 1991;13(5):926–39.
8. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, et al. Expert review on poliovirus immunity and transmission. Risk Anal. 2013;33(4):544–605.
9. Hird TR, Grassly NC., Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog. 2012;8(4):e1002599.
10. Duintjer Tebbens RJ, Pallansch MA, Kew OM, et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal. 2006;26(6):1471–505.
11. Platt LR, Estivariz CF, Sutter RW., Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis. 2014;210(suppl 1):S380–9.
12. Burns C, Diop O, Sutter RW, Kew OM., Vaccine-derived polioviruses. J Infect Dis. 2014;210(suppl 1):S283–93.
13. Global Polio Eradication Initiative. Global eradication of wild poliovirus type 2 declared [cited 30 November 2015]. Available from: http://www.polioeradication.org/mediaroom/newsstories/Global-eradication-of-wild-poliovirus-type-2-declared/tabid/526/news/1289/Default.aspx
14. Kew OM, Cochi SL, Jafari HS, et al. Possible eradication of wild poliovirus type 3—worldwide, 2012. MMWR Morb Mortal Wkly Rep. 2014;63(45):1031–3.
15. World Health Organization. Polio now [cited 14 August 2016]. Available from: http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx
16. Alexander LN, Seward JF, Santibanez TA, et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA. 2004;292(14):1696–701.
17. Kew O, Morris-Glasgow V, Landaverde M, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science. 2002;296(5566):356–9.
18. Duintjer Tebbens RJ, Pallansch MA, Kim JH, et al. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal. 2013;23(4):680–702.
19. MacCallum FO., Hypogammaglobulinaemia in the United Kingdom. VII. The role of humoral antibodies in protection against and recovery from bacterial and virus infections in hypogammaglobulinaemia. Spec Rep Ser Med Res Counc (G B). 1971;310:72–85.
20. Duintjer Tebbens RJ, Pallansch MA, Thompson KM., Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs. BMC Infect Dis. 2015;15:379.
21. World Health Organization. Global Polio Eradication Initiative: polio eradication and endgame strategic plan (2013–2018) (Report No. WHO/POLIO/13.02). Geneva, Switzerland: World Health Organization; 2013.
22. Global Polio Eradication Initiative. Global synchronisation and the switch [cited 4 May 2016]. Available from: http://polioeradication.org/news-post/global-synchronisation-and-the-switch/
23. The Cuba IPV Study Collaborative Group. Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. N Engl J Med. 2007;356(15):1536–44.
24. Chen RT, Hausinger S, Dajani AS, et al. Seroprevalence of antibody against poliovirus in inner-city preschool children. JAMA. 1996;275(21):1639–45.
25. Más Lago P, Bravo JR, Andrus JK, et al. Lesson from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies. Bull World Health Organ. 1994;72(2):221–5.
26. Duintjer Tebbens RJ, Thompson KM., Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. J Infect Dis. 2014;210(suppl 1):S485–97.
27. Duintjer Tebbens RJ, Hampton LM, Thompson KM., Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation. BMC Infect Dis. 2016;16:237.
28. Duintjer Tebbens RJ, Hampton LM, Thompson KM., Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use. BMC Infect Dis. 2016;16:231.
29. Thompson KM, Duintjer Tebbens RJ. Modeling the dynamics of oral poliovirus vaccine cessation. J Infect Dis. 2014;210(suppl 1):S475–84.
30. World Health Organization. GAP III: WHO Global Action Plan to minimize poliovirus facility-associated risk after type-specific eradication of wild polioviruses and sequential cessation of oral polio vaccine use [cited 9 November 2015]. Available from: http://polioeradication.org/wp-content/uploads/2016/12/GAPIII_2014.pdf
31. Global Polio Eradication Initiative. Responding to a poliovirus event and outbreak—Part 2: Protocol for poliovirus type 2 [cited 29 April 2016]. Available from: http://polioeradication.org/wp-content/uploads/2016/09/Responding-to-a-poliovirus-event-and-outbreak-SOPs-Part-2-Protocol-for-PV-Type-2_EN.pdf
32. John J, Giri S, Karthikeyan AS, et al. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial. Lancet. 2014;384(9953):1505–12.
33. Jafari H, Deshpande JM, Sutter RW, et al. Polio eradication. Efficacy of inactivated poliovirus vaccine in India. Science. 2014;345(6199):922–5.
34. Estivariz CF, Pallansch MA, Anand A, et al. Poliovirus vaccination options for achieving eradication and securing the endgame. Curr Opin Virol. 2013;3(3):309–15.
35. Okayasu H, Sutter RW, Jafari HS, Takane M, Aylward RB., Affordable inactivated poliovirus vaccine: strategies and progress. J Infect Dis. 2014;210(suppl 1):S459–64.
36. Resik S, Tejeda A, Mach O, et al. Needle-free jet injector intradermal delivery of fractional dose inactivated poliovirus vaccine: association between injection quality and immunogenicity. Vaccine. 2015;33(43):5873–7.
37. Resik S, Tejeda A, Mach O, et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine. 2015;33(2):307–13.
38. Resik S, Tejeda A, Sutter RW, et al. Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med. 2013;368(5):416–24.
39. Anand A, Zaman K, Estivariz CF, et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine. 2015;33(48):6816–22.
40. Duintjer Tebbens RJ, Kalkowska DA, Wassilak SGF, Pallansch MA, Cochi SL, Thompson KM., The potential impact of expanding target age groups for polio immunization campaigns. BMC Infect Dis. 2014;14:45.
41. Duintjer Tebbens RJ, Pallansch MA, Wassilak SGF, Cochi SL, Thompson KM., Combinations of quality and frequency of immunization activities to stop and prevent poliovirus transmission in the high-risk area of northwest Nigeria. PLoS One. 2015;10(6):e0130123.
42. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM., Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria. J Infect Dis. 2014;210(suppl 1):S412–23.
43. Kalkowska DA, Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SGF, Thompson KM., Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination. BMC Infect Dis. 2015;15(66):1.
44. Thompson KM, Duintjer Tebbens RJ. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission. BMC Infect Dis. 2015;15:374.
45. Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat. World Population Prospects. The 2012 Revision. Volume I: Comprehensive Tables 2013 (Report No. ST/ESA/SER.A/336). New York: United Nations Secretariat; 2013.
46. Nigeria/Africa Masterweb. Nigeria 2006 census figures [cited 11 February 2013]. Available from: http://www.nigeriamasterweb.com/Nigeria06CensusFigs.html
47. World Health Organization. WHO Guide for Standardization of Economic Evaluations of Immunization Programmes (Report No. WHO/IVB/0814). Geneva, Switzerland: Initiative for Vaccine Research, Department of Immunization, Vaccine, and Biologicals; December 2008.
48. Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16(2):231–50.
49. Bureau of Labor Statistics, US Department of Labor. Consumer price index. Available from: https://www.bls.gov/cpi/
50. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SGF, Thompson KM., An economic analysis of poliovirus risk management policy options for 2013–2052. BMC Infect Dis. 2015;15:389.
51. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, et al. Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs. Risk Anal. 2013;33(4):606–46.
52. Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SGF, Cochi SL., Modeling population immunity to support efforts to end the transmission of live polioviruses. Risk Anal. 2013;33(4):647–63.
53. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM., Modeling strategies to increase population immunity and prevent poliovirus transmission in two high-risk areas in northern India. J Infect Dis. 2014;210(suppl 1):S398–411.
54. Duintjer Tebbens RJ, Pallansch MA, Wassilak SGF, Cochi SL, Thompson KM., Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. BMC Infect Dis. 2016;16:137.
55. Thompson KM, Duintjer Tebbens RJ, Pallansch MA, et al. The risks, costs, and benefits of possible future global policies for managing polioviruses. Am J Public Health. 2008;98(7):1322–30.
56. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, et al. Economic analysis of the Global Polio Eradication Initiative. Vaccine. 2011;29(2):334–43.
57. Duintjer Tebbens RJ, Pallansch MA, Kew OM, et al. Uncertainty and sensitivity analyses of a decision analytic model for post-eradication polio risk management. Risk Anal. 2008;28(4):855–76.
58. Murray CJ, Lopez AD., The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability From Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, MA: Harvard University Press; 1996.
59. World Bank. Gross national income per capita 2014, Atlas method and PPP [cited 4 May 2016]. Available from: http://databank.worldbank.org/data/download/GNIPC.pdf
60. Wagner BG, Behrend MR, Klein DJ, Upfill-Brown AM, Eckhoff PA, Hu H., Quantifying the impact of expanded age group campaigns for polio eradication. PLoS One. 2014;9(12):e113538.
61. Blake IM, Martin R, Goel A, et al. The role of older children and adults in wild poliovirus transmission. Proc Natl Acad Sci U S A. 2014;111(29):10604–9.
62. World Health Organization Commission on Macroeconomics and Health. Macroeconomics and Health: Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. Geneva, Switzerland: World Health Organization; 2001.
63. Hutubessy R, Chisholm D, Edejer TT., Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc. 2003;1(1):8.
64. International Vaccine Access Center. Case Studies of IPV Introduction: Albania, Nigeria, and Tunisia. Baltimore, MD: Johns Hopkins Bloomberg School of Public Health; 2016.
65. UNICEF. Inactivated poliovirus vaccine alert - May 2016 [cited 14 February 2017]. Available from: https://www.unicef.org/supply/files/Inactivated_Polio_Vaccine_(IPV)_-may_2015_banner.pdf
66. Shuaibu FM, Birukila G, Usman S, et al. Mass immunization with inactivated polio vaccine in conflict zones—experience from Borno and Yobe States, North-Eastern Nigeria. J Public Health Policy. 2016;37(1):36–50.
67. Duintjer Tebbens RJ, Thompson KM., Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs. BMC Infect Dis. 2015;15:390.